Axsome Therapeutics, Inc. (AXSM)
179.25
-2.82
(-1.55%)
USD |
NASDAQ |
Oct 02, 16:00
179.15
-0.10
(-0.06%)
After-Hours: 20:00
Axsome Therapeutics Net Income (Quarterly) : -51.31M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -51.31M |
| March 31, 2026 | -64.54M |
| December 31, 2025 | -28.56M |
| September 30, 2025 | -47.23M |
| June 30, 2025 | -47.97M |
| March 31, 2025 | -59.41M |
| December 31, 2024 | -74.91M |
| September 30, 2024 | -64.60M |
| June 30, 2024 | -79.34M |
| March 31, 2024 | -68.36M |
| December 31, 2023 | -98.65M |
| September 30, 2023 | -62.20M |
| June 30, 2023 | -67.17M |
| March 31, 2023 | -11.22M |
| December 31, 2022 | -61.24M |
| September 30, 2022 | -44.82M |
| June 30, 2022 | -41.44M |
| March 31, 2022 | -39.63M |
| December 31, 2021 | -33.98M |
| September 30, 2021 | -34.88M |
| June 30, 2021 | -32.28M |
| March 31, 2021 | -29.26M |
| Date | Value |
|---|---|
| December 31, 2020 | -29.16M |
| September 30, 2020 | -22.92M |
| June 30, 2020 | -18.33M |
| March 31, 2020 | -32.48M |
| December 31, 2019 | -24.81M |
| September 30, 2019 | -19.14M |
| June 30, 2019 | -13.76M |
| March 31, 2019 | -10.64M |
| December 31, 2018 | -9.597M |
| September 30, 2018 | -8.282M |
| June 30, 2018 | -8.281M |
| March 31, 2018 | -4.806M |
| December 31, 2017 | -7.430M |
| September 30, 2017 | -6.434M |
| June 30, 2017 | -7.084M |
| March 31, 2017 | -7.995M |
| December 31, 2016 | -7.329M |
| September 30, 2016 | -7.195M |
| June 30, 2016 | -6.812M |
| March 31, 2016 | -5.866M |
| December 31, 2015 | -1.714M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Eli Lilly & Co. | 7.095B |
| Liquidia Corp. | 74.72M |
| Filana Therapeutics, Inc. | -8.603M |
| CorMedix, Inc. | 25.99M |
| Eloxx Pharmaceuticals, Inc. | -4.502M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 218.38M |
| Total Expenses (Quarterly) | 269.69M |
| EPS Diluted (Quarterly) | -0.9906 |
| Enterprise Value | 9.280B |
| Gross Profit Margin (Quarterly) | 92.47% |
| Profit Margin (Quarterly) | -23.50% |
| Earnings Yield | -2.10% |
| Normalized Earnings Yield | -2.071 |